Our PDX data showing the strong efficacy of the combination of fulvestrant/palbociclib cocktail with BPN14770 in endocrine-resistant ER+ PDXs is the first preclinical evidence suggesting a potential use of this highly promising inhibitor in refractory ER+ breast cancer. The gene discussed is ESR1; the disease is breast cancer.